Stacks Image 172
Dr. Gaël Hedou PhD – Chairperson of Board

Gaël received his PhD in Natural Sciences at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, in the field of Neuroscience and Neuropharmacology studying brain and behavioral plasticity related to drug addiction. Following a postdoc at the ETH on brain plasticity and repair, he joined the pharmaceutical industry originally at GlaxoSmithKline in Verona, Italy. Gael held several positions of increasing responsibility at GSK and subsequently Merck Serono KGaA in the field of psychiatric and neurological diseases. In 2013, Gael co-founded Relief Therapeutics SA which became listed on the Swiss SIX stock exchange in 2016 and he was the Group CEO until 2019. Gael continues his career as COO of Sonnet BioTherapeutics CH SA, a fully owned subsidiary of the NASDAQ-listed US-based Sonnet BioTherapeutics Inc in charge of the development of Sonnet’s clinical-stage assets. Gael is also the owner of Django Trading Sàrl, a consultancy and investment company based in Switzerland.
Dr. Kostas Kaloulis PhD - Board member and co-founder

Kostas has more than 18 years of experience in the biopharmaceutical industry, with roles in business development, corporate strategic innovation, entrepreneurship (3 start-ups) and technology transfer. Kostas is the CEO of Arctos Medical, a gene therapy company developing a new solution for specific forms of blindness and a Venture Partner at NanoDimension Capital. He co-founded the ReMedys Foundation to support clinical development of innovative products to treat orphan diseases.
Stacks Image 168
Stacks Image 35
Dr. Maximilien Murone PhD – Board member, CEO and co-founder

Maximilien is a Scientific Executive with experience in start-up establishment, management and fund raising. He joined Cellestia as co-founder in 2015 and COO in 2017, with 20+ years of experience in the pharma/life sciences industry. Before joining Cellestia, Maximilien served as the Managing Director for AdipoGen Life Sciences. In addition, Maximilien served for 10 years as Associate Director at Debiopharm International SA, where he was managing the Early Projects team. Maximilien holds a PhD from the Swiss Institute of Experimental Cancer Research, and an executive MBA from HEC Lausanne. He spent three years as postdoctoral researcher in the Department of Molecular Oncology at Genentech, Inc., South San Francisco, USA.
Stacks Image 157
Board of Directors